MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412142 | Name: Sulotroban

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sulotroban is an antiplatelet drug

Chemical Structure

Sulotroban
Sulotroban
CAS#72131-33-0

Theoretical Analysis

MedKoo Cat#: 412142

Name: Sulotroban

CAS#: 72131-33-0

Chemical Formula: C16H17NO5S

Exact Mass: 335.0827

Molecular Weight: 335.37

Elemental Analysis: C, 57.30; H, 5.11; N, 4.18; O, 23.85; S, 9.56

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Sulotroban; BM-13177; BM13177; BM 13177
IUPAC/Chemical Name
Acetic acid, (4-(2-((phenylsulfonyl)amino)ethyl)phenoxy)-
InChi Key
XTNWJMVJVSGKLR-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H17NO5S/c18-16(19)12-22-14-8-6-13(7-9-14)10-11-17-23(20,21)15-4-2-1-3-5-15/h1-9,17H,10-12H2,(H,18,19)
SMILES Code
O=C(O)COC1=CC=C(CCNS(=O)(C2=CC=CC=C2)=O)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 335.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kozłowska H, Baranowska-Kuczko M, Schlicker E, Kozłowski M, Zakrzeska A, Grzęda E, Malinowska B. EP₃ receptor-mediated contraction of human pulmonary arteries and inhibition of neurogenic tachycardia in pithed rats. Pharmacol Rep. 2012;64(6):1526-36. doi: 10.1016/s1734-1140(12)70950-7. PMID: 23406763. 2: Malinowska B, Zakrzeska A, Kurz CM, Göthert M, Kwolek G, Wielgat P, Braszko JJ, Schlicker E. Involvement of central beta2-adrenergic, NMDA and thromboxane A2 receptors in the pressor effect of anandamide in rats. Naunyn Schmiedebergs Arch Pharmacol. 2010 Apr;381(4):349-60. doi: 10.1007/s00210-010-0497-6. Epub 2010 Mar 3. PMID: 20198363. 3: Steib CJ, Bilzer M, Härtl JM, Beitinger F, Gülberg V, Göke B, Gerbes AL. Kupffer cell activation by hydrogen peroxide: a new mechanism of portal pressure increase. Shock. 2010 Apr;33(4):412-8. doi: 10.1097/SHK.0b013e3181b85934. PMID: 20118678. 4: Fu LW, Phan A, Longhurst JC. Myocardial ischemia-mediated excitatory reflexes: a new function for thromboxane A2? Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2530-40. doi: 10.1152/ajpheart.00790.2008. Epub 2008 Oct 24. PMID: 18952714; PMCID: PMC2614549. 5: Ishizuka T, Higashino H. TP receptor as a therapeutic target in atherosclerosis and related cardiovascular diseases. Recent Pat Cardiovasc Drug Discov. 2006 Nov;1(3):241-7. doi: 10.2174/157489006778777025. PMID: 18221089. 6: Ghuysen A, Dogné JM, Chiap P, Rolin S, Masereel B, Lambermont B, Kolh P, Tchana-Sato V, Hanson J, D'Orio V. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor. Cardiovasc Drug Rev. 2005 Spring;23(1):1-14. doi: 10.1111/j.1527-3466.2005.tb00153.x. PMID: 15867944. 7: Rolin S, Dogne JM, Vastersaegher C, Hanson J, Masereel B. Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors. Prostaglandins Other Lipid Mediat. 2004 Oct;74(1-4):75-86. doi: 10.1016/j.prostaglandins.2004.07.007. PMID: 15560117. 8: Dogné JM, de Leval X, Kolh P, Sanna V, Rolin S, Michaux C, Mauer M, David JL, Masereel B, Pirotte B. Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function. Prostaglandins Leukot Essent Fatty Acids. 2003 Jan;68(1):49-54. doi: 10.1016/s0952-3278(02)00236-3. PMID: 12538090. 9: Rolin S, Dogné JM, Michaux C, Delarge J, Masereel B. Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot Essent Fatty Acids. 2001 Aug;65(2):67-72. doi: 10.1054/plef.2001.0290. PMID: 11545621. 10: Dogné JM, Rolin S, de Leval X, Benoit P, Neven P, Delarge J, Kolh P, Damas J, David JL, Masereel B. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531. Cardiovasc Drug Rev. 2001 Summer;19(2):87-96. doi: 10.1111/j.1527-3466.2001.tb00057.x. PMID: 11484064. 11: Kudoh A, Matsuki A. Bradykinin-induced inositol 1,4,5-triphosphate in neonatal rat cardiomyocytes is activated by endotoxin. Shock. 2000 Dec;14(6):635-9. doi: 10.1097/00024382-200014060-00011. PMID: 11131914. 12: Dogné JM, de Leval X, Neven P, Rolin S, Wauters J, David JL, Delarge J, Massereel B. Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins Leukot Essent Fatty Acids. 2000 May;62(5):311-7. doi: 10.1054/plef.2000.0160. PMID: 10883063. 13: Dogné JM, de Leval X, Delarge J, David JL, Masereel B. New trends in thromboxane and prostacyclin modulators. Curr Med Chem. 2000 Jun;7(6):609-28. doi: 10.2174/0929867003374868. PMID: 10702629. 14: Masereel B, Damas J, Fontaine J, Lembege M, Lacan F, Nuhrich A, Delarge J, Pochet L, Dogne JM. Thromboxane A2 receptor antagonism in man and rat by a sulphonylcyanoguanidine (BM-144) and a sulphonylurea (BM-500). J Pharm Pharmacol. 1999 Jun;51(6):695-701. doi: 10.1211/0022357991772998. PMID: 10454046. 15: Dogné JM, Neven P, Damas J, Fontaine J, Rolin S, De Leval X, Delarge J, Masereel B. BM 144: an original thromboxane A2 receptor antagonist derived from torasemide. J Pharm Belg. 1999 Mar-Apr;54(2):57-8. PMID: 10380411. 16: López-Ongil S, Torrecillas G, Pérez-Sala D, González-Santiago L, Rodríguez- Puyol M, Rodríguez-Puyol D. Mechanisms involved in the contraction of endothelial cells by hydrogen peroxide. Free Radic Biol Med. 1999 Mar;26(5-6):501-10. doi: 10.1016/s0891-5849(98)00223-8. PMID: 10218638. 17: Ogawa T, Sugidachi A, Asai F, Koike H. Involvement of platelet-derived 5-hydroxytryptamine in thromboxane A2-induced aggregation in cat platelets. Blood Coagul Fibrinolysis. 1998 Apr;9(3):233-40. doi: 10.1097/00001721-199804000-00003. PMID: 9663705. 18: Stewart MW, Etches WS, Boshkov LK, Mant MJ, Gordon PA, Shaw AR. Platelet activation by a novel solid-phase agonist: effects of VWF immobilized on polystyrene beads. Br J Haematol. 1997 May;97(2):321-9. doi: 10.1046/j.1365-2141.1997.372681.x. PMID: 9163596. 19: Komiotis D, Wencel-Drake JD, Dieter JP, Lim CT, Le Breton GC. Labeling of human platelet plasma membrane thromboxane A2/prostaglandin H2 receptors using SQB, a novel biotinylated receptor probe. Biochem Pharmacol. 1996 Sep 13;52(5):763-70. doi: 10.1016/0006-2952(96)00359-0. PMID: 8765474. 20: Somova L. Prostaglandin H2/thromboxane A2 pathway in platelet aggregation and activity of Dahl salt-sensitive rat--a sulotroban study. Methods Find Exp Clin Pharmacol. 1996 Jun;18(5):309-13. PMID: 8817465.